Protein Kinase Inhibitors

Kinase Inhibitor

Carcinoma, Renal Cell

Pancreatic Neoplasms

Neuroendocrine Tumors

Gastrointestinal Stromal Tumors

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>Sunitinib is a kinase inhibitor present in SUTENT capsules as the malate salt. Sunitinib malate is described chemically as (2S)-2-hydroxybutanedoic acid with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1). The molecular formula is C22H27FN4O2 ∙ C4H6O5 and the molecular weight is 532.6 Daltons. The chemical structure of sunitinib malate is:<div class="Figure"><img alt="Chemical Structure" src="sutent-01.jpg"/></div>Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 25 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2.SUTENT (sunitinib malate) capsules are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone (K-25). The orange gelatin capsule shells contain titanium dioxide and red iron oxide; the caramel gelatin capsule shells contain titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide; and the yellow gelatin capsule shells contain titanium dioxide and yellow iron oxide. The white printing ink contains shellac, propylene glycol, sodium hydroxide, povidone, and titanium dioxide and the black printing ink contains shellac, propylene glycol, potassium hydroxide, and black iron oxide.</section>

SUTENT

sunitinib 37.5 MG Oral Capsule

sunitinib 37.5 MG Oral Capsule [Sutent]

sunitinib

Sutent

sunitinib 12.5 MG Oral Capsule

sunitinib 12.5 MG Oral Capsule [Sutent]

sunitinib 25 MG Oral Capsule

sunitinib 25 MG Oral Capsule [Sutent]

sunitinib 50 MG Oral Capsule

sunitinib 50 MG Oral Capsule [Sutent]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Reimbursement Information 

Online Sample Form

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Formulary Exception Letter 

Other HCP Resources - Access 

Appeals Checklist 

PA Checklist 

Enroll in Patient Savings Program 

Pfizer Patient Assistance Program 

Free 90-day Supply: For Uninsured Patients While Applying for Medicaid

HCP Office : Attest & Print Co-Pay Card 

Pfizer Oncology Patient Access Guide

Pfizer Oncology Patient Access Guide - Spanish 

Instructions For Use: Adjuvant Treatment of RCC 

Instructions For Use: Advanced RCC

Instructions For Use: Advanced Pancreatic Neuroendocrine Tumors (pNET) 

​​​​​​​Instructions For Use: Imatinib-resistant or Intolerant GIST